Cas:23052-80-4 (2R)-2-amino-3-phosphonopropanoic acid manufacturer & supplier

Chemical Name:(2R)-2-amino-3-phosphonopropanoic acid

CAS.NO:23052-80-4

Synonyms:(2S)-2-amino-3-phosphonopropionic acid;L(+)-2-Amino-3-phosphonopropionic acid;L(+)-2-Amino-3-phosphonopropionic acidL-AP3;(R)-2-Amino-3-phosphonopropanoic acid;(R)-(+)-2-AMINO-3-PHOSPHONOPROPIONIC ACID;L-AP3;(S)-(+)-2-amino-3-phosphonopropanoic acid;3-PHOSPHONO-L-ALANINE;MFCD00083169;Phosphonoalanine;(2R)-2-Amino-3-phosphonopropionic acid;L(+)-2-AMINO-3-PHOSPHONOPROPANOIC ACID;phosphoserine

Molecular Formula:C₃H₈NO₅P

Molecular Weight:169.07300

HS Code:2931900090

Physical and Chemical Properties:

Melting point:227-229ºC

Boiling point:481.6ºC at 760 mmHg

Density:1.763 g/cm3

Index of Refraction:

PSA:130.66000

Exact Mass:169.01400

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (2S)-2-amino-3-phosphonopropionic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,phosphoserine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L(+)-2-Amino-3-phosphonopropionic acidL-AP3 Use and application,(2S)-2-amino-3-phosphonopropionic acid technical grade,usp/ep/jp grade.

Related News: “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. (2R)-2-amino-3-phosphonopropanoic acid manufacturer The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. (2R)-2-amino-3-phosphonopropanoic acid supplier After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply. (2R)-2-amino-3-phosphonopropanoic acid vendor “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. (2R)-2-amino-3-phosphonopropanoic acid factory Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.